根治性前列腺切除术后非索引医院再入院的全国代表性研究:对打包支付模式的启示
该研究基于美国全国再入院数据库2010-2014年数据,分析根治性前列腺切除术后90天内索引与非索引医院再入院的病因、费用和预测因素。共214,473例患者中12,316例(5.7%)发生再入院,其中4,283例(30.6%)为非索引医院再入院。非索引再入院费用更高($10,751 vs $10,113,p<0.01),且心血管和非前列腺切除术相关并发症更常见。
要点
- 根治性前列腺切除术后90天再入院率为5.7%,其中30.6%为非索引医院再入院。
- 非索引再入院费用显著高于索引再入院($10,751 vs $10,113,p<0.01)。
- 微创手术、高容量机构手术及农村居住是非索引再入院的预测因素。
核心结论
- 非索引医院再入院与更高的再入院费用相关,费用差异由小部分再入院类型驱动。
- 在高容量中心行根治性前列腺切除术的获益需与更高的非索引再入院风险及费用仔细权衡。
研究设计与样本
- 回顾性队列研究,使用2010-2014年全国再入院数据库,纳入214,473例接受根治性前列腺切除术的前列腺癌患者。
- 比较索引与非索引医院再入院的 sociodemographic 因素、医院费用和90天再入院原因,并用多变量回归分析费用差异及非索引再入院的预测因素。
主要发现
- 12,316例(5.7%)发生90天再入院,其中4,283例(30.6%)为非索引医院再入院。
- 非索引再入院更常见于心血管特异性并发症(16.6% vs 10.3%)和非根治性前列腺切除术特异性并发症(49.4% vs 32.8%),各p<0.01。
- 多变量模型显示非索引再入院费用显著高于索引再入院($10,751 vs $10,113,p<0.01)。
- 心血管相关非索引再入院费用更高($12,995 vs $10,108,p<0.001),电解质相关非索引再入院费用也更高($4,962 vs $3,179,p=0.01)。
- 非索引再入院的预测因素包括微创根治性前列腺切除术(OR 1.28,95% CI 1.03-1.58)、在高容量机构手术(OR 2.02,95% CI 1.41-2.89)和居住在农村地区(人口少于50,000,OR 1.68,95% CI 1.21-2.35)。
临床怎么用
- 在打包支付模式下,需将非索引医院再入院纳入费用核算,因其费用更高且由特定并发症驱动。
- 对于微创手术、高容量中心手术及农村居住患者,应关注非索引再入院风险,优化出院后随访与管理。
- 区域化集中手术时,需平衡高容量中心的获益与非索引再入院及费用增加的风险。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Implementing episode based payment models requires a detailed understanding of health care utilization throughout the 90-day postoperative episode. This includes nonindex hospital readmissions, which currently do not exist for patients treated with radical prostatectomy. We compared the causes, costs and predictors of index vs nonindex hospital readmissions after radical prostatectomy. MATERIALS AND METHODS: We identified patients with prostate cancer who underwent radical prostatectomy from 2010 to 2014 in the Nationwide Readmissions Database. Sociodemographic factors, hospital costs and causes of 90-day readmissions were compared between index and nonindex hospital readmissions. Multivariable regression models were used to determine whether nonindex readmissions were more costly than index readmission for several causes of readmission and also to identify predictors of nonindex readmissions. RESULTS: Of the 214,473 patients treated with radical prostatectomy 12,316 (5.7%) experienced a 90-day readmission and 4,283 (30.6%) had a nonindex readmission. Nonindex readmissions were more likely for complications which were cardiovascular specific (16.6% vs 10.3%) and nonradical prostatectomy specific (49.4% vs 32.8%, each p <0.01). On multivariable modeling readmission costs were significantly higher for nonindex vs index readmissions ($10,751 vs $10,113, p <0.01). Cardiovascular and electrolyte related nonindex readmissions ($12,995 vs $10,108, p <0.001, and $4,962 vs $3,179, p=0.01, respectively) were more expensive. Nonindex hospital readmission predictors included minimally invasive radical prostatectomy (OR 1.28, 95% CI 1.03-1.58), radical prostatectomy done at a high volume institution (OR 2.02, 95% CI 1.41-2.89) and residence in a more rural location (less than 50,000 population OR 1.68, 95% CI 1.21-2.35). CONCLUSIONS: In this nationally representative study nonindex hospital readmissions were associated with higher readmission costs, which were driven by differences in a small subset of readmissions. The benefits of undergoing radical prostatectomy at a high volume center should be carefully balanced with the increased odds of nonindex hospital readmissions and higher costs associated with such centers as regionalization continues.
引用
- Chappidi MR, Stimson CJ, Kates M, et al. A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models. J Urol. 2019. PMID: 31479405. doi:10.1097/JU.0000000000000522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。